This article was originally published in The Tan Sheet
CHPA plans to launch educational programs to deter inappropriate use of OTC cough remedy active ingredient in the Spring or Summer 2003. In Nov. 20 statement, trade group notes dextromethorphan "does not produce physical addiction, lose effectiveness through increased tolerance or cause withdrawal, even in high experimental doses." Statement responds to local news reports describing teenagers' abuse of dextromethorphan, CHPA says...
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.